FDA tentatively OK’s Mylan’s pemetrexed; shares up 4%

The FDA tentatively approves Mylan N.V.’s (MYL +3.9%) pemetrexed, a generic version of Eli Lilly’s (LLY +1%) lung cancer med Alimta.

Tentative approval means that Mylan’s marketing application met the criteria for approval, but patent issues need to be resolved before full approval is granted.

https://seekingalpha.com/news/3495779-fda-tentatively-oks-mylans-pemetrexed-shares-4-percent